J.P. Morgan Sees Potential Vestas Guidance Upgrade Amid Strong Wind Energy Demand 
Trump Administration Delays DeepSeek and CXMT Trade Blacklist Designations Amid U.S.-China Tensions 
Qantas Unveils Wellness-Focused Nonstop Sydney-London Flights to Reduce Jet Lag 
Meta Seeks Legal Shield From Child-Harm Lawsuits Amid KOSA Talks 
Apple Signals Product Price Hikes Amid Rising Memory Chip Costs 
Samsung Gains Interest from BYD, Google, AMD as AI Chip Demand Strains TSMC Capacity 
Qantas Nears Launch of World’s Longest Non-Stop Flights to London and New York 
Trump Says Anthropic No Longer Seen as National Security Threat 
BHP Shares Fall as Jansen Potash Project Costs Surge 
Kingboard Holdings Shares Surge After HK$11.77 Billion Block Trade to Expand PCB and AI Supply Chain Business 
Frank Stronach Found Guilty of Sexual Assault and Indecent Assault in Ontario Court 
US Raises Concerns Over Possible ASML EUV Machine Transfer to China 
SpaceX Surpasses Amazon in Market Value as Post-IPO Rally Accelerates 
G7 Explores AI Access Deal With U.S. Amid Anthropic Restrictions 
SK Hynix Shares Hit Record High After Shipping Next-Generation HBM4E AI Memory Samples 
Obayashi to Acquire Multiplex in $526M Expansion Deal 
John Jumper Leaves Google DeepMind for Anthropic Amid Intensifying AI Talent Race 
SANTA MONICA, Calif., Jan. 06, 2016 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (NASDAQ:KITE) today announced that Arie Belldegrun, M.D., FACS, Chairman, President and Chief Executive Officer, will present at the 34th Annual J.P. Morgan Healthcare Conference on Thursday, January 14, 2016 at 8:30 AM Pacific Time. The event will be held in San Francisco at the Westin St. Francis Hotel.
The presentation will be webcasted and will be available through the Calendar of Events section of Kite's website at ir.kitepharma.com.
About Kite Pharma, Inc.
Kite Pharma, Inc., is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a primary focus on engineered autologous cell therapy (eACT™) designed to restore the immune system's ability to recognize and eradicate tumors. Kite is based in Santa Monica, CA. For more information on Kite Pharma, please visit www.kitepharma.com. Sign up to follow @KitePharma on Twitter at www.twitter.com/kitepharma.
CONTACT: Kite Pharma, Inc. Cynthia M. Butitta Chief Financial Officer and Chief Operating Officer 310-824-9999 For Media: Justin Jackson For Investor Inquiries: Lisa Burns Burns McClellan (212) 213-0006 [email protected] [email protected]
